Bond M, Jankowski M, Patel H, Karnik S, Strang A, Xu B, Rouse J, Koza S, Letwin B, Steckert J, Amphlett G, Scoble H
Genetics Institute, Inc, Andover, MA 01810, USA.
Semin Hematol. 1998 Apr;35(2 Suppl 2):11-7.
Mature human factor IX is a 55,000-d glycoprotein with a modular domain structure and numerous posttranslational modifications. A recombinant form of human factor IX (rFIX) has been produced from a Chinese hamster ovary cell line that was engineered for high-level protein processing and expression. To ensure that the recombinant molecule contains the requisite structural and functional features of the plasma-derived form, rFIX was subjected to detailed biochemical and biophysical characterization. The laboratory studies showed that the posttranslational modifications and primary, secondary, and tertiary structures of rFIX were similar to those of plasma-derived factor IX (pdFIX). In addition, rFIX displayed a high degree of purity and a product release specification for specific activity that is > or = 200 IU/mg.
成熟的人凝血因子IX是一种55000道尔顿的糖蛋白,具有模块化的结构域结构和众多的翻译后修饰。重组人凝血因子IX(rFIX)是从经过工程改造以进行高水平蛋白质加工和表达的中国仓鼠卵巢细胞系中产生的。为确保重组分子具有血浆来源形式所需的结构和功能特征,对rFIX进行了详细的生化和生物物理表征。实验室研究表明,rFIX的翻译后修饰以及一级、二级和三级结构与血浆来源的凝血因子IX(pdFIX)相似。此外,rFIX显示出高度的纯度,其比活性的产品放行标准≥200IU/mg。